Strikingly, 100% of mice treated with DEXP&A&N and Flt3L rejected tumor re-challenge and remained tumor-free at 100 days after cessation of treatment, whereas no mice survived in PBS groups on day 66 after tumor re-challenge (Fig. 7d, e), confirming the formation of effective immunological memory. The gene discussed is FLT3LG; the disease is neoplasm.